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A simple High Performance Liquid Chromatographic method with
UV detection was developed for quantification of Cyclosporin A
(CysA) in skin samples after in vitro penetration studies. The peptide
was recovered from two different layers of skin, the stratum corneum
and the epidermis plus dermis ([E+D]), by vortex homogenization
and bath sonication in an organic solvent (methanol). Recovery
of CysA from skin was about 85%, and CysA was estimated by
HPLC using a RP-18 column, UV detection at 210 nm and
acetonitrile:water (67:33 v/v) as the mobile phase. The
quantification limit was 150ng/mL. The assay was linear from 0.15-
500 g/mL. The within-day and between-day assay precision and
accuracy were studied at three concentration levels (1, 10 and 20
g/mL). The coefficients of variation and deviation from the
theoretical values were lower than 5%. The method described has
a potential application to in vitro penetration studies of CysA using
porcine skin as a biological membrane model.
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INTRODUCTION
Cyclosporin A (CysA), a cyclic undecapeptide, is an
effective inhibitor of both humoral and cell mediated
immune responses by specifically and reversibly
interacting with T lymphocytes (Borel, 1990). It has been
used clinically for the prophylaxis and treatment of organ
rejection in transplants as well as in the treatment of
immune related disorders of skin such as psoriasis (Fisher
et al., 1988; Linden et al., 1999; Lamelland et al., 2003).
Its systemic administration has several shortcomings, often
associated with drug variable pharmacokinetics, narrow
therapeutic index, and large number of side effects
(Duncan et al., 1990; Christians et al., 2000,).
Topical administration of CysA for treatment of skin
diseases is interesting to directly target local lesions without
major bioavailability problems, and to reduce the systemic side
effects (Duncan et al., 1990; Choi et al., 1995; Boinpally et
al., 2004). Several attempts have been made to increase
CysA delivery to skin, which is hindered by the barrier function
of the stratum corneum (SC). Penetration enhancers, physical
techniques and drug delivery systems have been evaluated as
strategies to increase CysA penetration in the skin (Duncan
et al., 1990; Choi et al., 1995; Mizoguchi et al., 1992; Wang
et al., 1997a; Wang et al., 1997b; Wang et al., 1998; Guo et
al., 2000; Boinpally et al., 2004; Verma e Fahr, 2004).
The topical delivery of CysA requires the development
of a robust and sensitive method to extract and quantify this
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drug in the skin in order to predict if adequate amounts of
drug reaches viable layers of skin. To date, few studies
involve the development of methods to quantify CysA in skin
models (Wang et al., 1997a; Wang et al., 1997b; Wang et
al., 1998; Guo et al., 2000; Boinpally et al., 2004). The
present study aimed at developing a simple method to
extracted CysA from SC and epidermis (E) plus dermis (D)
of porcine ear skin ([E+D]), and to assay the drug using
High Pressure Liquid Chromatography (HPLC). The
suitability of the HPLC method to quantify CysA in
homogenates of SC and [E+D] was demonstrated.
MATERIAL AND METHODS
Standard solutions and chemicals
A 1mg/mL standard solution of CysA in methanol
was prepared and stored at –5 oC. Working solutions (0.1
to 500 g/mL) were prepared by appropriate dilutions with
methanol and stored at -5 o C. Solvents used for extraction
and the mobile phase were of chromatographic grade
(Omnisolve, Merck).
Equipment and chromatographic conditions
The Shimadzu liquid chromatography equipment
consisted of a Model LC10 AD solvent pump, a Rheodyne
injector fitted with a 20 L loop, a Model SPD-10A variable
wavelength UV detector operating at 210 nm, a Model
CTO-10A column oven at 60 oC and a model SCL-10A
controller system. The separation was on a Lichrospher
100RP-18 column (5 m, Merck Darmstadt, Germany).
The mobile phase was 67% acetonitrile and 33% water
and the flow rate, 1 mL/min.
Skin preparations
The penetration of CysA in the skin was assessed using
an in vitro model of porcine ear skin, as previously described.
(Lopez et al., 2001). Briefly, the skin from the outer surface
of a freshly excised porcine ear was carefully dissected
(making sure that the subcutaneous fat was maximally
removed), stored at -20o C, and used within a month.
CysA recovery from porcine skin
The absolute recovery of CysA from skin tissue was
determined by spiking skin sections (1.77 cm2) with a CysA
solution in methanol (100 g/mL). The spiked skin sections
(n=7) were allowed to rest for 20 minutes. CysA was
assessed in two different skin layers: stratum corneum and
epidermis plus dermis. To separate the stratum corneum
(SC) from the remaining epidermis (E) and dermis (D), skin
sections were subjected to tape stripping. The skin was
stripped with 15 pieces of adhesive tape, and the tapes
containing the SC were immersed in 5 mL of methanol.
The system was vortex stirred for 2 min. The methanolic
phase was filtered using a 0.45 m membrane, and the
resulting filtrate assayed for CysA by HPLC. The
remaining [E+D] was cut in small pieces, vortex mixed for
2 min in 2 mL of methanol, and homogenized by bath
sonication for 30 minutes. The resulting mixture was then
filtrated using 0.45 m membranes, and CysA was
determined in the filtrate by chromatographic assay.
In vitro skin penetration
The methodology developed for CysA quantification
in porcine skin was used to determine CysA skin
penetration after in vitro cutaneous penetration
experiments. On the day of the experiment, the cleaned
porcine ear skin was mounted in a Franz diffusion cell
(diffusion area of 1.77 cm2; Hanson Research, Chatsworth,
CA, USA), with the stratum corneum facing the donor
compartment and the dermis facing the receptor
compartment, which was filled with a receptor phase of
100 mM phosphate buffer (pH 7.2) containing ethanol
(10%). Previous studies have used receptor phases
containing up to 33% of ethanol to increase drug solubility
in the receptor phase (Choi et al., 1995, Guo et al., 2000).
The system was maintained at 37 oC and under constant
stirring. A hundred milligrams of a solution composed of
CysA at 4% (w/w) in propylene glycol (n=5) was applied
to the surface of the stratum corneum (in the donor
compartment), and the concentration of CysA in the SC
and [E+D] was determined at 12 h post-application.
At the end of the experiment, skin surfaces were
thoroughly washed with distilled water to remove excess
formulation. CysA was extracted from SC and [E+D]
using the methodology described above (in the item CysA
recovery from porcine skin). The amounts of drug
detected in SC and in [E+D] were indicatives of drug
penetration in the skin.
Assay specifications
Validation of a method is the process by which a
method is tested by the developer or user for reliability,
accuracy and preciseness of its intended purpose. Based
on this, we evaluated several parameters to demonstrate
that the analytical procedure is suitable for analyzing CysA
in skin samples (ANVISA resolution number 899).
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Linearity responses were verified by using
methanolic solutions of CysA in concentrations ranging
from 0.1 to 500 g/mL. The precision and accuracy of the
method were tested in a within-day and between-day basis.
For the determination of the within-day precision and
accuracy, ten (10) CysA methanolic solution replicate
aliquots at concentrations of 1, 10 and 20 g/mL were
analyzed. The between-day precision and accuracy were
determined by analyzing 5 aliquots of the same CysA
solutions on five consecutive days. The range, defined as
the interval between the high and low levels of the analyte
studied, was obtained based on the linearity.
The precision of the assay was calculated as the relative
standard deviation (coefficient of variation, CV), whereas the
accuracy was calculated as the relative error of the mean,
between expected and calculated concentrations, according
to the following equation: Accuracy (%) = (calculated mean
- theoretical/theoretical) x 100.
The sensitivity of the method was evaluated by
determining the lower limit of quantification and the
detection limit. The lower limit of quantification was set as
the lowest CysA concentration that could be determined
with adequate precision and accuracy, whereas the lower
limit was the lowest CysA concentration that could be
detected but not quantified under the stated experimental
conditions (Causon, 1997, Santana et al., 2004). The
detection and quantification limits were calculated by
analyzing diluted solutions of CysA in concentrations
ranging from 75-200 ng/mL.
The selectivity of the method was verified by
evaluating the interference of skin compounds and of the
adhesive tape on the assay of CysA. Samples of control
skin (treated with Milli Q water) were submitted to the
same procedure to extract CysA, as described in the item
CysA recovery from porcine skin. The homogenates of
SC and [E+D] were subject to HPLC assay.
Calibration curves
Calibration curves to assay CysA in skin samples
were constructed by assaying methanolic solutions of the
drug in concentrations ranging from 1 to 30 g/mL.
RESULTS AND DISCUSSION
The therapy with CysA requires regular therapeutic
drug monitoring and blood concentration guided dosing
regimens have been recommended (Christians et al., 2000).
CysA and its metabolites have been quantified in blood and
other biological matrices by several methods, including the
use of immunoassay kits, radioactive labeling of CysA and
liquid scintillation assays. Good results have been obtained
using HPLC (Kroschsorur et al.,1997, Safarcik et al.,
2001). To date, few studies aimed at developing
methodologies to assay CysA from skin samples.
Although HPLC methods have adequate specificity,
several difficulties have been faced due to the
characteristics of the peptide. HPLC-UV methods
described have used appropriate reversed phase
chromatographic columns maintained at relatively high
temperatures (70 oC), necessary for adequate peak
shaping. In general, the mobile phases used for HPLC
assay are composed of high proportions of organic solvents,
and long CysA retention times are observed (Kroschsorur
et al.,1997, Husek, 1997). The low UV range absorption
peak of the peptide (around 200 nm) makes its detection
difficult and susceptible to interferences (Taylor et al.,
1998). The synthesis of fluorescent derivatives of CysA
has already been studied in an attempt to increase the
sensitivity and selectivity of HPLC assay for CysA (Fois
and Ashley, 1989). However, to date, no efficient
derivatization method has been demonstrated. In addition,
skin samples presents proteins, lipids and other compounds
that might interfere with CysA analysis, increasing its
difficulty. Thus, a suitable method to extract CysA from
skin samples and to assay this peptide with little
interference is necessary.
The UV-HPLC method described in the present
study has the advantage of a rapid and sensitive
quantification of CysA retained in the skin. In addition,
maintaining the chromatographic column at 60 oC increases
its working life. Figure 1 shows a typical profile of a CysA
chromatogram.
FIGURE 1 - Chromatograms of CysA standard solutions
in methanol at concentrations of (a) 1 g/mL, (b) 5 g/mL
and (c) 10 g/mL. CysA was assessed by HPLC using a
RP-18 chromatographic column, mobile phase composed
of acetonitrile and water (67:33 v/v), flow rate of 1mL/min
and UV detection at 210 nm.
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Peak areas of the drug linearly correlated with
concentrations in the range of 0.15-500 g/mL. The
equation for a typical calibration curve, obtained by the
least squares linear regression was y=26662x + 105.4,
r=0.999.
The within-day precision and accuracy of the assay
were obtained by sequential analysis of CysA solutions in
methanol at three distinct concentrations (1, 10 and 20 g/
mL). The within-day assay coefficients of variation (CV)
for CysA were lower than 5% and all between-day assay
coefficients of variation were below 3% (Table 1). The
within-day and between-day assay accuracies were found
to be 2.3 and 1.9% respectively for 1 g/mL, 3.1 and 4.9%
for 10 g/mL, and 0.3 and 0.4% for 20 g/mL.
The detection limit of the assay was 100 ng/mL. The
lowest concentration quantified by this method with
acceptable precision and accuracy was 150 ng/ml. This
limit is adequate for the assessment of CysA retained in the
skin, since the drug is lipophilic and it is expected to be
retained within the SC and [E+D] rather than to permeate
across the skin.
The selectivity of the method was verified by
evaluating the interference of compounds from skin and
from the adhesive tape on the assay of CysA. Figure 2
shows chromatograms of homogenates of SC and [E+D]
from control skin sections (treated with Milli Q water). The
compounds of the skin and of the adhesive tape used for
the tape stripping procedure did not interfere with the
analysis of CysA. The HPLC method developed here
proved to be selective since the retention time for other
compounds present in the skin or in the adhesive tape,
analyzed under the same chromatographic conditions of
CysA analysis, was not similar to those obtained for CysA.
The amount of CysA extracted from the skin (SC and
[E+D]) corresponds to 85% of the spiked dose (n=7). The
method for CysA extraction from skin layers described in
this paper resulted in a high recovery of the drug compared
to other studies, which demonstrates its suitability for
application on cutaneous penetration studies. Accordingly,
the method reported by Wang et al. (1997a) resulted in an
average 74% recovery of CysA from [E+D]. Moreover,
the method of drug extraction described here also involves
fewer steps and is less time-consuming than others
described in the literature (Guo et al., 2000, Verma and
Fahr, 2004). This method led, however, to the extraction of
other compounds from the skin and from the adhesive tape
together with CysA, but the HPLC method proved to be
selective for the drug.
The methods developed for CysA quantification in
skin samples by UV-HPLC demonstrated to be suitable for
CysA assay in different skin layers after in vitro
penetration studies. At 12 h post-application, 18.2±3.9 g/
cm2 (n=5) of CysA was detected in the [E+D], and
48.8±6.5 g/cm2 in the SC (Figure 3).
In conclusion, the combined procedures of
extraction and HPLC assay of CysA in the SC and
[E+D] is efficient in terms of drug recovery and rapid
manipulation. In addition, the HPLC method has the
required precision and accuracy. Considering the
therapeutic advantages of topical administration of
CysA formulations in the treatment of cutaneous
diseases, the proposed methodology for CysA assay in
samples of different skin layers, from in vitro and even
so in vivo studies, could be very important in the design
TABLE I - Analysis of the precision and accuracy of the
HPLC method for CysA
Nominal standard Precision Accuracy










n, number of determination; CV, coefficient of variation,
a lower limit of quantification
FIGURE 2 - Chromatograms referring to analyses of
homogenates of SC (gray line) and [E+D] (bold black line)
compared to the profile of a 5 g/mL CysA solution (dashed
black line) to evaluate the selectivity of the method.
Conditions: mobile phase: acetonitrile: water (67:33 v/v);
flow rate: 1mL/min; UV detection: 210 nm.
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and evaluation of  drug delivery using topical
formulations.
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RESUMO
Análise por CLAE da ciclosporina contida em
amostras de pele provenientes de estudos de
penetração cutânea in vitro.
Neste estudo foi desenvolvido um método simples
utilizando Cromatografia Líquida de Alta Eficiência
(CLAE) com detecção no UV para quantificação de
Ciclosporina A (CysA) em amostras de pele após es-
tudos de penetração cutânea in vitro. O peptídeo foi
extraído do estrato córneo e da epiderme sem estra-
to córneo + derme ([E+D]) através de agitação em
vórtex e sonicação utilizando um solvente extrator
(metanol). A recuperação da CysA de ambas as ca-
madas da pele foi de 85%, conforme estimado por
CLAE utilizando coluna RP-18, detecção em 210 nm
e fase móvel  composta de acetonitri la e água
(67:33, v/v). O limite de quantificação do peptídeo
utilizando este método cromatográfico foi de 150
ng/mL. O método mostrou-se linear na faixa de 0,15-
500 g/mL. A precisão e exatidão intra e inter-en-
saio foram avaliadas utilizando três concentrações
distintas (1, 10 e 20 g/mL). Os valores de coefici-
ente de variação e o desvio do valor teórico foram
inferiores a 5%. O método descrito pode ser utiliza-
do para determinação da CysA após estudos de
penetração cutânea in vitro utilizando pele de por-
co como modelo de membrana.
UNITERMOS: CLAE. Ciclosporina A. Pele. Penetra-
ção cutânea in vitro.
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